The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
 
Tanya Jindal
No Relationships to Disclose
 
Cindy Jiang
No Relationships to Disclose
 
Omar Alhalabi
Consulting or Advisory Role - Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Ikena Oncology (Inst)
 
Dimitra Rafailia Bakaloudi
No Relationships to Disclose
 
Rafee Talukder
No Relationships to Disclose
 
Matthew Davidsohn
No Relationships to Disclose
 
Amanda Nizam
Consulting or Advisory Role - AVEO
 
Amy K Taylor
No Relationships to Disclose
 
Charles B Nguyen
No Relationships to Disclose
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Exelixis; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AVEO; Exelixis; Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen
 
Cameron Pywell
No Relationships to Disclose
 
Nancy B. Davis
Consulting or Advisory Role - Janssen Biotech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst)
 
Hamid Emamekhoo
Consulting or Advisory Role - Cardinal Health; Exelixis; Seagen; Seagen
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Medscape; Natera; Onclive; Physicans' Education Resource; Research to Practice; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); GeneCentric (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar; Nektar
Honoraria - Bristol Myers Squibb Foundation
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Joaquim Bellmunt
Stock and Other Ownership Interests - Rainier Therapeutics
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate Bladder Cancer
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Matthew T Campbell
Honoraria - AstraZeneca; Axdev; Curio Science; Exelixis; Medscape; Seagen; Targeted Oncology
Consulting or Advisory Role - EMD Serono; Exelixis; Pfizer; SeaGen
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; SeaGen
Other Relationship - Curio Science
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte (Inst); Merck (Inst); Nektar (Inst); Taiho Oncology (Inst)